An interventional study of Trinase and placebo capsule in Symptomatic Irreversible Pulpitis (SIP), Postoperative Pain After Endodontic Treatment and Endodontic Disease, sponsored by Fayoum University. Completed at 1 site in Egypt. Open to male participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-09-30.
Sponsored by Fayoum University · Not applicable, Interventional, and Treatment
This study aims to determine whether Trinase, an enzyme-based anti-inflammatory medication, can reduce pain after root canal treatment in patients with symptomatic irreversible pulpitis. A total of 400 male patients aged 18 to 50 years who present with moderate to severe tooth pain were randomly assigned to receive either a Trinase tablet or a placebo 30 minutes before treatment. All root canal procedures were performed in a single visit using standard endodontic techniques.
Pain levels were measured on a Visual Analogue Scale (VAS) before treatment and at 6, 12, 24, and 48 hours after treatment. Patients recorded the number of pain-relief tablets they take during the first 48 hours. The goal of the study is to see whether Trinase can lower post-operative pain and reduce the need for analgesic medication compared with placebo. This information may help improve pain management for patients undergoing root canal therapy.
Symptomatic irreversible pulpitis is a common endodontic condition characterized by severe inflammatory dental pain. Although root canal treatment (RCT) is effective in removing the inflamed pulp tissue, many patients continue to experience pain during the first 24-48 hours after treatment. Post-operative endodontic pain affects patient comfort, satisfaction, and clinical workflow, making pain control an essential component of evidence-based endodontic care.
Traditional pharmacological methods for managing post-operative dental pain include nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids. While these medications are effective, they are also associated with potential gastrointestinal and systemic adverse effects, especially when used repeatedly. As a result, there is growing interest in alternatives that can reduce inflammation and discomfort while minimizing systemic risks. Enzyme-based anti-inflammatory therapies, including combinations of trypsin, bromelain, and rutin, have been shown in medical and dental literature to provide meaningful reductions in pain, edema, and inflammation following surgical procedures. These proteolytic enzymes act by breaking down inflammatory mediators, reducing tissue permeability, and modulating cytokine responses. Trinase, a formulation containing trypsin, bromelain, and rutin, is widely used in postoperative care in other medical fields, yet its role in managing pain following endodontic procedures has not been adequately studied.
This randomized, double-blind, placebo-controlled clinical trial is designed to evaluate whether administering Trinase before root canal treatment can reduce the intensity of post-operative pain in patients diagnosed with symptomatic irreversible pulpitis. A total of 400 systemically healthy male patients, aged 18 to 50 years, were recruited from the Endodontics Department at Fayoum University. The study population is limited to male participants to standardize biological pain variability and hormonal influences on pain perception. Eligible patients presented with restorable mandibular molar teeth and moderate to severe preoperative pain confirmed both clinically and radiographically.
Participants were randomly assigned to one of two equal study arms. The Trinase group received a single oral Trinase tablet 30 minutes before treatment. The placebo group received a visually identical tablet administered under the same conditions. An assistant not involved in treatment prepared and code all medication envelopes, ensuring allocation concealment. Both the operator and the participants were blinded to group assignment.
All treatments were performed in a single visit using standardized endodontic procedures. After local anesthesia, rubber-dam isolation, and access preparation, canal patency were confirmed using stainless steel hand files. Working length determined electronically and confirmed radiographically. Mechanical instrumentation were performed using Protaper Next rotary instruments according to manufacturer instructions. Irrigation will be performed using 2.5% sodium hypochlorite and EDTA gel lubricant. Upon completion of cleaning and shaping, canals will be dried, obturated using a modified single-cone technique with resin-based sealer, and restored temporarily with intermediate restorative material. All procedures are performed by a single experienced operator to eliminate inter-operator variability.
The primary outcome measure is postoperative pain intensity assessed using a 10-cm Visual Analogue Scale (VAS). Patients will record their pain levels at baseline and at 6, 12, 24, and 48 hours after treatment. Pain will be categorized using validated VAS cutoff values. The secondary outcome measure is the total number of analgesic tablets consumed within 48 hours following treatment. Participants will receive a standardized pain diary to document both pain levels and analgesic intake.
Statistical analysis will be conducted using non-parametric tests due to expected non-normal distribution of pain scores. Between-group differences will be analyzed using the Mann-Whitney test, and within-group comparisons across time points will be performed using the Friedman test followed by appropriate post-hoc analysis. The significance level will be set at p ≤ 0.05. Sample size was calculated using PS software to detect clinically relevant differences in postoperative pain with an anticipated dropout rate accounted for by enrolling 400 participants.
The study protocol has been reviewed and approved by the Fayoum University Supreme Committee for Scientific Research Ethics (FU-SCSRE). Written informed consent will be obtained from each participant. The study involves minimal risk, as Trinase is a commercially available medication with a well-established safety profile and the placebo carries no known risks. The duration of active participation for each subject is approximately 48 hours, corresponding to the postoperative observation period. No additional radiographs or invasive procedures beyond standard clinical care will be performed.
This study aims to determine whether Trinase can serve as a simple, safe, and effective adjunct to improve postoperative patient comfort following root canal therapy. The results may help clarify the role of enzyme-based anti-inflammatory medications in endodontic pain management and potentially reduce reliance on traditional analgesics with known adverse effects.
130 studies on the registry are indexed under Dental Pulp Diseases; 37 are open to participants now.
This study's enrollment of 400 is above the median of 52 across 108 interventional studies indexed under Dental Pulp Diseases.
Browse Dental Pulp Diseases studies →Fayoum University is the lead sponsor of 148 studies on the registry; 44 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Medically compromised patients ( or higher)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients received one tablet of Trinase (trypsin, bromelain, and rutin) orally 30 minutes before single-visit root canal treatment (RCT). RCT was performed under local anesthesia (2% lidocaine with 1:80,000 epinephrine) using a rubber dam and standard endodontic techniques. Postoperative pain was assessed using the Visual Analogue Scale (VAS) at 6, 12, 24, and 48 hours. Ibuprofen 400 mg was allowed as rescue analgesia if needed, and consumption was recorded.
Drug: Trinase
Patients received one identical-appearing placebo tablet orally 30 minutes before single-visit root canal treatment (RCT). RCT was performed using the same anesthesia, instrumentation, irrigation, and obturation protocol as the Trinase group. Postoperative pain was assessed using the Visual Analogue Scale (VAS) at 6, 12, 24, and 48 hours. Ibuprofen 400 mg was allowed as rescue analgesia if needed, and consumption was recorded.
Drug: placebo capsule
One tablet of Trinase (proteolytic enzyme combination: trypsin, bromelain, and rutin) administered orally 30 minutes prior to root canal treatment. Used as premedication to reduce postoperative pain and inflammation.
One identical-appearing placebo tablet administered orally 30 minutes prior to root canal treatment. Used as control.
Post-operative pain intensity assessed by Visual Analogue Scale (VAS)
Pain intensity was recorded by patients on a 10-cm Visual Analogue Scale (VAS), where 0 = no pain and 100 = pain as bad as it could be. Scores were categorized as no pain (0-4 mm), mild (5-44 mm), moderate (45-74 mm), severe (75-100 mm). Pain intensity was measured at baseline and at 6, 12, 24, and 48 hours after root canal treatment.
Time frame: Baseline, 6, 12, 24, and 48 hours after root canal treatment
Number of analgesic tablets consumed within 48 hours post-treatment
Total number of rescue analgesic tablets (ibuprofen 400 mg) taken by patients within 48 hours after root canal treatment, as recorded or provided in patient charts during follow-up.
Time frame: Within 48 hours post-treatment
Plan to share: Yes — De-identified individual participant data (IPD) including demographics, baseline VAS, postoperative VAS scores (6, 12, 24, 48h), and analgesic consumption will be shared. Data will be anonymized (no names, IDs, or dates) and provided in CSV/SPSS format. IPD will be available 6 months after publication of primary results and for 5 years thereafter. Access requires a signed data use agreement specifying research purpose and ethics approval. Contact: Dr. Sara Samir Elmallah (sara.elmallah@fayoum.edu.eg).
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.